Mesenchymal stromal stem cell therapy (Cyndacel-M) in a flowable dermal matrix (Excellagen) for chronic diabetic wounds.
Latest Information Update: 10 Nov 2014
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Chronic wounds
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gene Biotherapeutics; Orbsen Therapeutics
Most Recent Events
- 26 Jun 2014 New trial record